E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10004936 |
E.1.2 | Term | Bipolar depression |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of lurasidone (20-120mg/day flexibly dosed) in combination with lithium or divalproex compared to placebo (in combination with lithium or divalproex) for the treatment of subjects with bipolar I disorder, most recent episode depressed with or without rapid cycling disease course (≥4 episodes of mood disturbance but < 8 episodes in the previous 12 months), and without psychotic features (diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria) as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score. |
|
E.2.2 | Secondary objectives of the trial |
The key secondary objectives of this study are to evaluate the efficacy of lurasidone (20-120mg/day, flexibly dosed) when added to treatment with lithium and divalproex as measured by: - Global severity, assessed by the Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) - Subject self-report of functional impairment associated with bipolar depressive symptoms, assessed by the Sheehan Disability Scale (SDS) total score.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Subjects 18 to 75 years of age, with bipolar I disorder, most recent episode depressed with or without rapid cycling disease course (≥ 4 episodes of mood disturbance but < 8 episodes in the previous 12 months) and without psychotic features (diagnosed by DSM-IV-TR criteria). The current episode of major depression associated with bipolar I disorder must be confirmed by the investigator and noted in the source records. - Subjects must have a lifetime history of at least one bipolar manic or mixed manic episode. It is strongly recommended that a reliable informant (e.g., family member or caregiver) be available to confirm this history -Subject’s current major depressive episode is ≥ 4 weeks and less than 12 months in duration - MADRS total score ≥ 20 (at both screening and baseline visits) - YMRS total score ≤ 12 (at both screening and baseline visits) - Lithium or divalproex levels must be within the protocol-defined therapeutic range (0.6-1.2 mEq/L for lithium or 50-125 ug/mL for divalproex) at screening and at least 28 days prior to the screening visit. The lithium or divalproex serum level obtained at least 28 days prior to screening must be documented in source records based on laboratory reports, chart records or communication from a health professional. All preparations of lithium, divalproex (including extended-release formulations), or valproic acid will be permitted. |
|
E.4 | Principal exclusion criteria |
- Diagnosis of an Axis I or Axis II disorder, other than bipolar I disorder, that is the primary focus of treatment within 3 months prior to screening - Subject scores ≥ 4 on MADRS item number 10 (suicidal thoughts) at screening or baseline - History of non-response to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode - Imminent risk of suicide or injury to self, others, or property - Subject has been hospitalized for a manic or mixed episode within the 60 days prior to randomization |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline in MADRS total score after 6 weeks of treatment (Day 42). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 14 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |